Erika A Zannou from Pennington, NJ, age 52

Dual Acting Pharmaceutical Compositions Based On Superstructures Of Angiotensin Receptor Antagonist/Blocker (Arb) And Ne Utral Endopeptidase (Ep) Inhibitor
view source
US Patent:

20100267786, Oct 21, 2010
Filed:

Nov 4, 2008
Appl. No.:

12/741251
Inventors:

Suliman Al-Fayoumi - Morristown NJ, US
Jiahui Hu - Bridgewater NJ, US
Natrajan Kumaraperumal - Wayne NJ, US
Alan E. Royce - Saylorsburg PA, US
Colleen Ruegger - Morris Plains NJ, US
Erika A. Zannou - Edison NJ, US
International Classification:

A61K 31/41
A61P 9/12
A61P 9/10
US Classification:

514381
Abstract:

Solid oral dosage forms, especially tablets, of a pharmaceutical composition comprising a supramolecular complex can be formed from a direct compression process or a compaction process such as roller compaction. Such solid oral dosage forms feature an immediate release profile that allows for fast release of the therapeutic agent. A particularly useful supramolecular complex is trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3′-methyl-2′-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate]hemipentahydrate.

Pharmaceutical Formulations Of Bisphosphonates
view source
US Patent:

20070134319, Jun 14, 2007
Filed:

Dec 22, 2004
Appl. No.:

10/583646
Inventors:

Erika Zannou - Edison NJ, US
Simon Bateman - Randolph NJ, US
Madhusudhan Pudipeddi - Edison NJ, US
Alan Royce - Saylorsburg PA, US
Abu Serajuddin - Queens NY, US
Assignee:

NOVARTIS AG - Basel
International Classification:

A61K 9/20
A61K 31/66
US Classification:

424464000, 514102000
Abstract:

A pharmaceutical formulation comprising an oral dosage form containing a bisphosphonic acid or a salt thereof and an inactive ingredient selected from: an ester of a medium chain fatty acid, or a lipophilic polyethylene glycol ester, said inactive ingredient having a hydrophilic lipophilic balance (HLB) of from about 1 to about 30.

Dual-Acting Pharmaceutical Compositions Based On Superstructures Of Angiotensin Receptor Antagonist/Blocker (Arb) And Neutral Endopeptidase (Nep) Inhibitor
view source
US Patent:

20210085631, Mar 25, 2021
Filed:

Dec 2, 2020
Appl. No.:

17/109716
Inventors:

- Basel, CH
Jiahui HU - Bridgewater NJ, US
Natrajan KUMARAPERUMAL - Wayne NJ, US
Alan E. ROYCE - Saylorsburg PA, US
Colleen RUEGGER - Morris Plains NJ, US
Erika A. ZANNOU - Edison NJ, US
International Classification:

A61K 31/216
A61K 9/20
A61K 31/41
Abstract:

Solid oral dosage forms, especially tablets, of a pharmaceutical composition comprising a supramolecular complex can be formed from a direct compression process or a compaction process such as roller compaction. Such solid oral dosage forms feature an immediate release profile that allows for fast release of the therapeutic agent. A particularly useful supramolecular complex is trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate-(S)-3′-methyl-2′-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate]hemipentahydrate.